Show simple item record

dc.contributor.authorSpurrell, ELen_US
dc.contributor.authorLockley, Men_US
dc.date.accessioned2015-02-20T10:30:25Z
dc.date.issued2014en_US
dc.identifier.issn1754-6605en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/6573
dc.descriptionCopyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.description.abstractThe vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms by which to evade host immunity in their constant quest for growth and survival. Tumour-associated antigens (TAAs) are one of the fundamental triggers of the immune response. They are important because they activate, via major histocompatibility complex (MHC), the T cell response, an important line of defense against tumourigenesis. However, the persistence of tumours despite host immunity implies that tumour cells develop immune avoidance. An example of this is the up-regulation of inhibitory immune checkpoint proteins, by tumours, which induces a form of self-tolerance. The majority of monoclonal antibodies in clinical practice have been developed to target tumour-specific antigens. More recently there has been research in the down-regulation of immune checkpoint proteins as a way of increasing anti-tumour immunity.en_US
dc.format.extent441 - ?en_US
dc.languageengen_US
dc.relation.ispartofEcancermedicalscienceen_US
dc.subjectCTLA4en_US
dc.subjectPD-1en_US
dc.subjectPDL-1en_US
dc.subjectadaptive immunityen_US
dc.subjectimmune toleranceen_US
dc.subjectmonoclonal antibodyen_US
dc.subjecttumour-associated antigensen_US
dc.titleAdaptive immunity in cancer immunology and therapeutics.en_US
dc.typeArticle
dc.identifier.doi10.3332/ecancer.2014.441en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/25075215en_US
pubs.notesNot knownen_US
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Barts Cancer Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Barts Cancer Institute/Molecular Oncology
pubs.organisational-group/Queen Mary University of London/REF
pubs.organisational-group/Queen Mary University of London/REF/REF - SMD - BCI
pubs.publication-statusPublished onlineen_US
pubs.volume8en_US
qmul.funderInflammatory cytokines and oncolytic viruses in ovarian cancer::CRUKen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record